Cell biobank as a necessary infrastructure for the development and implementation of mesenchymal stem cell-based therapy in the treatment of anthracycline-induced cardiotoxicity. Literature review and own data
Open Access
- 31 December 2020
- journal article
- Published by Silicea - Poligraf, LLC in Cardiovascular Therapy and Prevention
- Vol. 19 (6), 2733
- https://doi.org/10.15829/1728-8800-2020-2733
Abstract
Cardiovascular diseases, along with cancer, are the leading causes of death worldwide. Although modern pharmacological treatment of various cardiomyopathies can slow the development of myocardial dysfunction, they have limited effectiveness in patients with end-stage disease. Many researchers believe that heart transplantation is the only radical treatment in this case. However, the lack of donors and the high operation cost require careful selection of surgical candidates. With the introduction of molecular and cell biology into medical practice, today, stem cell therapy can become an alternative method of nonsurgical restoration of myocardial functions. The most studied and attractive is the use of mesenchymal stem cells (MSCs). MSCs differ from hematopoietic stem cells used as support for hematopoiesis in high-dose chemotherapy by the following features: pronounced trophic effect, immune tolerance, the ability to suppress alloreactivity and autoimmune disorders. An important stage in the implementation of cell therapy is the creation of a cell biobank of MSCs. In A.F.Tsyb Medical Radiological Research Center, this work has been carried out since1984. Asignificant number of experimental studies have been carried out, confirming the possibility of clinical implementation of this approach. A method for obtaining stable cultures of MSCs and cardiomyoblasts from bone marrow cells was developed and approvals were obtained. Experimental studies of cell therapy are also being conducted to overcome anthracycline-induced cardiotoxicity in cancer patients.This article is devoted to practical application of MSC-based therapy, in particular, in cancer patients with cardiotoxicity, as well as to the issues of creating a cell biobank for treatment with MSCs.Keywords
This publication has 25 references indexed in Scilit:
- Addition of Mesenchymal Stem Cells Enhances the Therapeutic Effects of Skeletal Myoblast Cell-Sheet Transplantation in a Rat Ischemic Cardiomyopathy ModelTissue Engineering, Part A, 2014
- Allogeneic Human Mesenchymal Stem Cell Therapy (Remestemcel-L, Prochymal) as a Rescue Agent for Severe Refractory Acute Graft-versus-Host Disease in Pediatric PatientsTransplantation and Cellular Therapy, 2013
- The MSC: An Injury DrugstoreCell Stem Cell, 2011
- Allogeneic mesenchymal stem cell transplantation in seven patients with refractory inflammatory bowel diseaseGut, 2011
- Safety and Immunological Effects of Mesenchymal Stem Cell Transplantation in Patients With Multiple Sclerosis and Amyotrophic Lateral SclerosisArchives of Neurology, 2010
- Allogenic mesenchymal stem cells transplantation in refractory systemic lupus erythematosus: a pilot clinical studyAnnals Of The Rheumatic Diseases, 2010
- Opportunities and challenges for mesenchymal stem cell-mediated heart repairCurrent Opinion in Lipidology, 2007
- Adult mesenchymal stem cells for tissue engineering versus regenerative medicineJournal of Cellular Physiology, 2007
- Anthracycline-induced cardiomyopathySeminars in Oncology, 2001
- Doxorubicin Cardiotoxicity in the RatJournal of Cardiovascular Pharmacology, 1984